Prof Danny Rischin
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
539 Scholarly works
8 Projects
HIGHLIGHTS
2026
Journal article
Treatment of Radiation-Associated Dysphagia with Statins (TRADstat): protocol for a prospective, single-site, single-arm pilot trial
DOI: 10.1136/bmjopen-2026-1250772026
Journal article
C-Post Study of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma: Impact of Adjuvant Radiotherapy on Disease-Free Survival
DOI: 10.1016/j.ijrobp.2026.06.0862026
Journal article
Individual Differences in Resilience and Optimism in Relation to PROMs Commonly Used in Head and Neck Cancer Trials: A Prospective Longitudinal Observational Study
DOI: 10.1016/j.ijrobp.2026.06.5672026
Research grants (ARC, NHMRC, MRFF)
Expanding the Role of Immunotherapy in Cutaneous and Mucosal Head and Neck Squamous Cell Carcinomas
2025
Research grants (ARC, NHMRC, MRFF)
Novel Treatment of Radiation Associated Dysphagia With Statins (TRADstat)
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12020
Research grants (ARC, NHMRC, MRFF)
Defining the Role of Immunotherapy and Immune Biomarkers in Head and Neck and Cutaneous Squamous Cell Carcinomas
RECENT SCHOLARLY WORKS
2026
Journal article
Patient Reported Symptom Trajectories during and after Radiotherapy (RT) for Human Papillomavirus-Associated Oropharyngeal Cancer (HPVOPC): A TROG 12.01 Secondary Analysis
DOI: 10.1016/j.ijrobp.2026.06.5542026
Journal article
Radiation Therapy Target Objectives for Tonsillar Cancer Treated With Unilateral Radiation Therapy—A Replanning Study From TROG 12.01
DOI: 10.1016/j.ijrobp.2025.12.0582026
Journal article
Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT)
DOI: 10.1016/j.radonc.2026.1115502026
Journal article
Immunotherapy response and resistance in cutaneous squamous cell carcinoma
DOI: 10.20935/acadonco83392026
Journal article
PD-L1 CPS ≥10 population subgroup analysis of KEYNOTE-412: Pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for unresected locally advanced head and neck squamous cell carcinoma.
DOI: 10.1200/jco.2026.44.16_suppl.60632026
Journal article
A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1–positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.
DOI: 10.1200/jco.2026.44.16_suppl.tps61292026
Journal article
C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.
DOI: 10.1200/jco.2026.44.16_suppl.6083
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Expanding the Role of Immunotherapy in Cutaneous and Mucosal Head and Neck Squamous Cell Carcinomas